. Author manuscript; available in PMC: 2020 Dec 1.

Published in final edited form as: Surg Pathol Clin. 2019 Sep 27;12(4):921–930. doi: 10.1016/j.path.2019.08.002

Table 3.

Common Commercially available molecular testing platforms for thyroid fine needle aspiration

Platforms	Testing methods	PPV ^a	NPV	Rule in test	Rule out test
Thyroseq genomic classifier version 3 ²⁸	Next generation sequencing platform of 112 genes: mutations, fusions, copy number alterations and gene expression	66%	97%	Yes	Yes
Afirma gene expression classifier ^34,60,62	Microarray essay of mRNA expression of 142 genes	42%	93–97%	No	Yes
ThyGenX/ThyraMIR ^34,62	Combined test of NGS mutation detection and miRNA classifier	74–82%	92–94%	Yes	Yes
RosettaGX ^34,62	microRNA classifier	42%	92%	No	Yes

mRNA: messenger RNA, miRNA: microRNA.

^a.

The PPV is calculated using a surgical diagnosis of carcinoma or NIFTP.